Exelixis Stock News

Tandem Capital Management Corp ADV lessened its stake in Exelixis, Inc. (NASDAQ:EXEL) by 37.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,650 shares of the biotechnology company’s stock after selling 5,770 shares during the quarter. Tandem Capital Management Corp […]

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that accomplished technology executive Jacqueline (Jacky) Wright has been elected to the companys Board of Directors. Ms. Wrights appointment took effect on December 16, 2021. Ms. Wright has decades of technology experience and is widely recognized for her expertise in digital transformation, both in the public and private sectors. She currently serves as Corporate Vice President & Chief Digital Officer, U.S.

ERYTECH Pharma (NASDAQ:ERYP) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Profitability This table compares ERYTECH Pharma and Exelixis’ net margins, return on equity and return on assets. […]

Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.

Exelixis (EXEL) begins the dose-escalation stage of its study evaluating XL092 in combination with immuno-oncology therapies in patients with advanced solid tumors.

Stephens Investment Management Group LLC lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 17.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,432,147 shares of the biotechnology companys stock after buying an additional 508,967 shares during the period. []

– STELLAR-002 is second trial to evaluate XL092, a next-generation tyrosine kinase inhibitor, in advanced cancers – ALAMEDA, Calif. --(BUSINESS WIRE)--Dec. 15, 2021-- Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of STELLAR-002, a phase 1b trial evaluating

But both have been crashing so far in 2021.

But both have been crashing so far in 2021.

Sales are climbing at these biotech companies -- and more potential products are on the horizon.

A small investment can go a long way with this mix of growth, income, and value stocks.

Sales are climbing at these biotech companies -- and more potential products are on the horizon.

A small investment can go a long way with this mix of growth, income, and value stocks.

Cambiar Investors LLC lessened its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.5% during the 3rd quarter, Holdings Channel reports. The firm owned 617,306 shares of the biotechnology companys stock after selling 2,939 shares during the quarter. Cambiar Investors LLCs holdings in Exelixis were worth $13,050,000 as of its most recent filing with the []

It''s been a feast for bulls operating on the daily timeframe, as exel has now gone up 4 of the past 5 days. The post Exelixis Inc (EXEL): Price Now Near $16.56; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .